Skip to main content

Table 2 Clinical data and laboratory results of group 2 and controls (two evaluations after the same time of follow-up)

From: Increased incidence of precocious and accelerated puberty in females during and after the Italian lockdown for the coronavirus 2019 (COVID-19) pandemic

Variable Group 2 Controls
before lockdown after lockdown visit 1 visit 2
Population number 12 12 11 11
Chronological age at diagnosis (yr) 7.47 ± 0.53 7.41 ± 0.61
Chronological age at follow-up (yr) 7.95 ± 0.49 8.26 ± 0.47 7.93 ± 0.51 8.31 ± 0.53
Time between the two visits (yr) 0.31 ± 0.02 0.38 ± 0.02
Height, SDS 0.87 ± 1.22 0.89 ± 1.25 0.86 ± 1.13 0.90 ± 1.16
BMI, SDS 0.61 ± 0.85 0.92 ± 0.87 0.60 ± 0.93 0.69 ± 0.94
Δ BMI, SDS 0.32 ± 0.02*** 0.09 ± 0.01***
Tanner stage, percentage
 II 47.6 -*** 63.6 54.5
 III 52.4 71.4*** 36.4 45.5
 IV 28.6***
 V
Basal LH (IU/L) 0.8 ± 0.6* 1.4 ± 0.6* 0.9 ± 0.7 1.1 ± 0.7
Basal FHS (IU/L) 1.9 ± 1.5 1.5 ± 1.3 1.6 ± 1.4 1.5 ± 1.2
Peak LH at GnRH stimulation (IU/L) 9.6 ± 3.4* 12.5 ± 3.1* 9.0 ± 3.1 11.7 ± 3.3
Basal estradiol (females only) 111.3 ± 15.2** 133.4 ± 18.3** 113.8 ± 13.9 119.1 ± 15.4
Uterine length, cm 4.10 ± 0.49* 4.59 ± 0.47* 4.00 ± 0.35 4.35 ± 0.37
Ovarian volume, cm3 2.94 ± 0.52* 3.43 ± 0.48* 2.86 ± 0.46 3.18 ± 0.46
Electronic device use (h) 1.6 ± 0.9*** 3.9 ± 1.5***
  1. * = p < 0.05; ** P = 0.005; *** = p < 0.0005. BA bone age, CA chronological age, SDS standard deviation score, BMI body mass index, LH luteinizing hormone, FSH follicle-stimulating hormone, GnRH gonadotropin releasing hormone test